Identification of microRNAs that promote erlotinib resistance in non-small cell lung cancer
Related Experiment Video
Updated: Dec 14, 2025
Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016
1Department of Biological Sciences, West Lafayette, IN, USA; Purdue Life Sciences Interdisciplinary Program (PULSe), West Lafayette, IN, USA.
Abstract:
Lung cancer is the leading cause of cancer-related deaths, demanding improvement in current treatment modalities to reduce the mortality rates. Lung cancer is divided into two major classes with non-small cell lung cancer representing ~84% of lung cancer cases. One strategy widely used to treat non-small cell lung cancer patients includes targeting the epidermal growth factor receptor (EGFR) using EGFR-inhibitors, such as erlotinib, gefitinib, and afatinib. However, most patients develop resistance to EGFR-inhibitors within a year post-treatment. Although some mechanisms that drive resistance to EGFR-inhibitors have been identified, there are many cases in which the mechanisms are unknown. Thus, in this study, we examined the role of microRNAs in driving EGFR-inhibitor resistance. As mediators of critical pro-growth pathways, microRNAs are severely dysregulated in multiple diseases, including non-small cell lung cancer where microRNA dysregulation also contributes to drug resistance. In this work, through screening of 2019 mature microRNAs, multiple microRNAs were identified that drive EGFR-inhibitor resistance in non-small cell lung cancer cell lines, including miR-432-5p.
Insights
This study identifies microRNAs, including miR-432-5p, that drive resistance to epidermal growth factor receptor (EGFR) inhibitors in non-small cell lung cancer. Understanding these microRNAs can help overcome treatment resistance and improve patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality, with epidermal growth factor receptor (EGFR) inhibitors being a common treatment.
- Acquired resistance to EGFR inhibitors is a major clinical challenge, limiting treatment efficacy in NSCLC patients.
- The role of microRNAs in mediating drug resistance in NSCLC remains incompletely understood.
Purpose of the Study:
- To investigate the role of microRNAs in the development of resistance to EGFR inhibitors in non-small cell lung cancer.
- To identify specific microRNAs that contribute to EGFR inhibitor resistance in NSCLC cell lines.
Main Methods:
- Screening of 2019 mature microRNAs in NSCLC cell lines.
- Identification of microRNAs that confer resistance to EGFR inhibitors.
Main Results:
- Multiple microRNAs were identified as drivers of EGFR inhibitor resistance in NSCLC.
- miR-432-5p was identified as one such microRNA contributing to EGFR inhibitor resistance.
Conclusions:
- MicroRNA dysregulation plays a significant role in mediating EGFR inhibitor resistance in NSCLC.
- Targeting identified microRNAs may offer novel therapeutic strategies to overcome drug resistance in NSCLC patients.
More Related Videos
09:45An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
Published on: May 21, 2019
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
01:22MicroRNAs
01:22MicroRNAs
03:18Non-LTR Retrotransposons